Trinity Biotech Receives Increased Orders For TrinScreen HIV, Total Orders Received To Date For Supply In 2024 To ~$6M; Increased Its Expected 2024 Sales Revenue For TrinScreen HIV To Over $8M
Trinity Biotech Receives Increased Orders For TrinScreen HIV, Total Orders Received To Date For Supply In 2024 To ~$6M; Increased Its Expected 2024 Sales Revenue For TrinScreen HIV To Over $8M
Trinity Biotech plc (NASDAQ:TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional orders for TrinScreen HIV, bringing total orders received to date for supply in 2024 to approximately $6 million.
專注於人類診斷和糖尿病管理解決方案（包括可穿戴生物傳感器）的商業階段生物技術公司三一生物技術公司（納斯達克股票代碼：TRIB）今天宣佈，它已收到TrinScreen HIV的大量額外訂單，使2024年迄今收到的供應訂單總額達到約600萬美元。
The Company has successfully scaled up production to meet the increased demand for its rapid HIV tests.
該公司已成功擴大產量，以滿足對其快速HIV檢測不斷增長的需求。
As a result of this strong momentum in demand and the successful scaling of production capacity, the Company has increased its expected 2024 sales revenue for TrinScreen HIV to over $8 million.
由於這種強勁的需求勢頭和成功擴大產能，該公司已將其2024年TrinScreen HIV的預期銷售收入提高到800萬美元以上。
譯文內容由第三人軟體翻譯。